Tags

Type your tag names separated by a space and hit enter

Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
Cardiovasc Ther. 2010 Dec; 28(6):361-8.CT

Abstract

BACKGROUND

Chronic kidney disease (CKD) is an increasingly health disease all around the world with a high burden of mortality and cardiovascular (CV) morbidity rate. Even when renal replacement therapy is reached, more than half patients die, mainly for CV causes due either to uremia-related cardiovascular risk factors (such as anemia, hyperhomocysteinemia, mineral bone disease-CKD with hyperparathyroidism, oxidative stress, hypoalbuminemia, chronic inflammation, prothrombotic factors) or to traditional ones (age, male gender, diabetes, obesity, hypertension, smoking, insulin levels, family history, dyslipidemia). Among the latter causes dyslipidemia represents one of the major, potentially correctable risk factor.

METHODS AND RESULTS

Statins have demonstrated to effectively and safely reduce cholesterol levels in CKD patients. Here we will examine the effects of statins on CV risk factors in CKD patients and particularly in patients on dialysis treatment, in the light of the unfavorable results of the large trials 4D and AURORA, recently published, underlining the role of malnutrition/inflammation as confounding factor. Probably it will be that only with a real prevention, starting statins even in the early stages of CKD, as indicated by post hoc analysis of large trials, that we will reach results in reducing the mortality rate in CKD patients. In the meanwhile, all the other remediable CV risk factors have to be at the same time corrected.

Links

Aggregator Full Text

Authors+Show Affiliations

Scarpioni R
Unit of Nephrology and Dialysis, Guglielmo da Saliceto Hospital, Piacenza, Italy. rscarpioni@hotmail.com
Ricardi M
No affiliation info available
Melfa L
No affiliation info available
Cristinelli L
No affiliation info available

MeSH

Cardiovascular DiseasesChronic DiseaseDyslipidemiasEvidence-Based MedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsKidney DiseasesRenal DialysisRisk AssessmentRisk FactorsTreatment Outcome

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20553296

Citation

Scarpioni, Roberto, et al. "Dyslipidemia in Chronic Kidney Disease: Are Statins Still Indicated in Reduction Cardiovascular Risk in Patients On Dialysis Treatment?" Cardiovascular Therapeutics, vol. 28, no. 6, 2010, pp. 361-8.
Scarpioni R, Ricardi M, Melfa L, et al. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment? Cardiovasc Ther. 2010;28(6):361-8.
Scarpioni, R., Ricardi, M., Melfa, L., & Cristinelli, L. (2010). Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment? Cardiovascular Therapeutics, 28(6), 361-8. https://doi.org/10.1111/j.1755-5922.2010.00182.x
Scarpioni R, et al. Dyslipidemia in Chronic Kidney Disease: Are Statins Still Indicated in Reduction Cardiovascular Risk in Patients On Dialysis Treatment. Cardiovasc Ther. 2010;28(6):361-8. PubMed PMID: 20553296.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment? AU - Scarpioni,Roberto, AU - Ricardi,Marco, AU - Melfa,Luigi, AU - Cristinelli,Luciano, PY - 2010/6/18/entrez PY - 2010/6/18/pubmed PY - 2011/2/22/medline SP - 361 EP - 8 JF - Cardiovascular therapeutics JO - Cardiovasc Ther VL - 28 IS - 6 N2 - BACKGROUND: Chronic kidney disease (CKD) is an increasingly health disease all around the world with a high burden of mortality and cardiovascular (CV) morbidity rate. Even when renal replacement therapy is reached, more than half patients die, mainly for CV causes due either to uremia-related cardiovascular risk factors (such as anemia, hyperhomocysteinemia, mineral bone disease-CKD with hyperparathyroidism, oxidative stress, hypoalbuminemia, chronic inflammation, prothrombotic factors) or to traditional ones (age, male gender, diabetes, obesity, hypertension, smoking, insulin levels, family history, dyslipidemia). Among the latter causes dyslipidemia represents one of the major, potentially correctable risk factor. METHODS AND RESULTS: Statins have demonstrated to effectively and safely reduce cholesterol levels in CKD patients. Here we will examine the effects of statins on CV risk factors in CKD patients and particularly in patients on dialysis treatment, in the light of the unfavorable results of the large trials 4D and AURORA, recently published, underlining the role of malnutrition/inflammation as confounding factor. Probably it will be that only with a real prevention, starting statins even in the early stages of CKD, as indicated by post hoc analysis of large trials, that we will reach results in reducing the mortality rate in CKD patients. In the meanwhile, all the other remediable CV risk factors have to be at the same time corrected. SN - 1755-5922 UR - https://www.unboundmedicine.com/medline/citation/20553296/Dyslipidemia_in_chronic_kidney_disease:_are_statins_still_indicated_in_reduction_cardiovascular_risk_in_patients_on_dialysis_treatment L2 - https://doi.org/10.1111/j.1755-5922.2010.00182.x DB - PRIME DP - Unbound Medicine ER -